PCRX Pacira BioSciences
- 30.820
- -0.690-2.19%
- 30.810
- -0.010-0.03%
Pacira BioSciences News
We Think That There Are Issues Underlying Pacira BioSciences' (NASDAQ:PCRX) Earnings
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) stock was strong after they recently reported robust earnings. However, we think that shareholders may be missing some concerning details in the numbers. N
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes Due 2029
PDF Version TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior no
Pacira Biosciences Announces Proposed Offering of $250M Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.
HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
HC Wainwright & Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $57 price target.
Pacira BioSciences Is Maintained at Overweight by Barclays
Pacira BioSciences Is Maintained at Overweight by Barclays
Pacira BioSciences Price Target Cut to $38.00/Share From $40.00 by Barclays
Pacira BioSciences Price Target Cut to $38.00/Share From $40.00 by Barclays
Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $38
Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and lowers the price target from $40 to $38.
Analyst Ratings For Pacira BioSciences
6 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:PCRX) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments,
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating
Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $36 to $57, according to analysts polled by Capital IQ. Price: 30.05, Change: +3.54, Percent Change: +13.35
Pacira Biosciences Up Nearly 12%, On Track for Largest Percent Increase Since November 2020 -- Data Talk
Pacira Biosciences, Inc. (PCRX) is currently at $29.64, up $3.14 or 11.83% --Would be highest close since March 20, 2024, when it closed at $30.02 --On pace for largest percent increase since Nov. 9
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences Price Target Cut to $43.00/Share From $45.00 by Needham
Pacira BioSciences Price Target Cut to $43.00/Share From $45.00 by Needham
Pacira BioSciences Is Maintained at Buy by Needham
Pacira BioSciences Is Maintained at Buy by Needham
Needham: Maintains Pacira BioSciences (PCRX.US) rating, adjusted from buy to buy rating, and adjusted target price from $45.00 to $43.00.
Needham: Maintains Pacira BioSciences (PCRX.US) rating, adjusted from buy to buy rating, and adjusted target price from $45.00 to $43.00.
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to $43.
Pacira BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 62.2% Needham $45 → $43 Maintains Buy 04/09/2024 69.75% Needham → $45 Reiterates Buy → Buy 03/0
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
PDF Version TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million
Pacira BioSciences Reports Q1 2024 Results: Aligns With EPS Projections and Announces $150 ...
Analysis
Price Target
No Data
